RBC Capital analyst Leonid Timashev upgraded Design Therapeutics (DSGN) to Outperform from Sector Perform with a price target of $13, up from $6.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics Reports Q3 2025 Financial Results
- Design Therapeutics reports Q3 EPS (30c), consensus (34c)
- Design Therapeutics Advances DT-168 Study for Fuchs Dystrophy
- Design Therapeutics Advances DT-216P2 Study for Friedreich’s Ataxia
- Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia